바이오파크진단

비상장계속사업자

BioParkDx Inc.

박정호

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

바이오파크진단

Business Reg. No. 2048647969 · CEO 박정호

I.Investment Overview

Target바이오파크진단 (2048647969)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명바이오파크진단
영문명BioParkDx Inc.
대표자박정호
사업자등록번호2048647969
법인등록번호1101115320819
설립일2014.01.20
종업원수17명

V.Workforce

17

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW588.92021439.42022149.1202381.12024
영업이익100M KRW173.12021129.1202215.92023-102024
순이익100M KRW128.92021106.6202211.120235.92024
Item2024202320222021
자산총계305.1억원302.4억원306.4억원297.1억원
부채총계9.6억원10.4억원23.1억원116.3억원
자본총계295.5억원291.9억원283.3억원180.8억원
매출액81.1억원149.1억원439.4억원588.9억원
영업이익-10억원15.9억원129.1억원173.1억원
순이익5.9억원11.1억원106.6억원128.9억원

VII.Financial Ratios

FY2024 basis

-12.29%

영업이익률

7.23%

순이익률

1.92%

ROA

1.98%

ROE

3.24%

부채비율

96.87%

자기자본비율

VIII.R&D Activity

Fields 보건의료 > 의료기기·S/W 안전관리 · 보건의료 > 기타 보건의료

Keywords 온도관리, 정도관리, 알람, 시스템, 종합병원

YearProjectsPapersPatents
2020001
2019101
2018103
2017100
2016001
2015100

IX.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

바이오파크진단 투심보고서 | Alpha Lenz